STOCK TITAN

OKAMI MEDICAL APPOINTS RHONDA ROBB AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Okami Medical Inc. (Ticker: OMI) appoints Rhonda Robb as President and CEO, bringing over 25 years of leadership and commercial experience in the medical device industry. The company is preparing to commercialize the LOBO Vascular Occlusion System, a next-generation technology addressing peripheral vascular conditions.
Positive
  • None.
Negative
  • None.

ALISO VIEJO, Calif., Jan. 8, 2024 /PRNewswire/ -- Okami Medical Inc., a medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular intervention, today announced the appointment of Rhonda Robb as President and Chief Executive Officer.

Rhonda is a proven medical device executive with more than 25 years of leadership and commercial experience. She most recently served as Chief Operating Officer at Cardiovascular Systems, Inc., a leader in the treatment of peripheral and coronary artery disease. Prior to Cardiovascular Systems, Rhonda served as the Vice President and General Manager for Heart Valve Therapies at Medtronic, where she led the transcatheter and surgical heart valve franchises. She also serves on the Board of Directors for 4C Medical.

"Rhonda brings a proven track record and a wealth of experience to the company," said Bob Rosenbluth, PhD, Co-Founder and Chairman of the Board of Okami Medical. "She shares our commitment and passion for providing patients and physicians with access to advanced technologies that address the numerous challenges in peripheral vascular occlusion. We are thrilled to have her leading the company into the next phase of expansion and growth."

"I am honored to have the opportunity to lead Okami Medical at this exciting time as we prepare to commercialize our LOBO Vascular Occlusion System," said Rhonda. "The team has done a tremendous job of taking the system from the conceptual stage through clinical validation. LOBO is a next-generation technology that is delivering remarkable clinical performance and is uniquely suited to transform and expand the treatment of patients suffering from peripheral vascular conditions."

About Okami Medical, Inc.

Okami Medical, Inc. is a privately-held medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular intervention. Okami is the second portfolio company of Inceptus Medical LLC, a medical device incubator. Inari Medical, Inc. (NASDAQ: NARI), Inceptus' first portfolio company, is pioneering approaches to treat venous thromboembolism and other diseases. Okami is backed by members of the board of directors, U.S. Venture Partners (www.usvp.com) and medical device industry veterans. For more information, please visit www.okamimedical.com.

Source:
Okami Medical, Inc.
949-446-9710
info@okamimedical.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/okami-medical-appoints-rhonda-robb-as-president-and-chief-executive-officer-302027577.html

SOURCE Okami Medical Inc.

Rhonda Robb has been appointed as the President and Chief Executive Officer of Okami Medical Inc.

The ticker symbol for Okami Medical Inc. is OMI.

The LOBO Vascular Occlusion System is a next-generation technology aimed at addressing peripheral vascular conditions with remarkable clinical performance.

Rhonda Robb brings over 25 years of leadership and commercial experience in the medical device industry to Okami Medical Inc.

Okami Medical Inc. is preparing to commercialize the LOBO Vascular Occlusion System and expand its reach in addressing peripheral vascular conditions.
Inari Medical Inc

NASDAQ:NARI

NARI Rankings

NARI Latest News

NARI Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing

About NARI

inari medical is a medical device company pioneering devices for the interventional treatment of vascular thrombi and emboli.